Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BIO.B Stock Forecast 2026-2027
$304.15
Current Price
$8.14B
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BIO.B Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
BIO.B Price Momentum
0.0%
1 Week Change
+16.4%
1 Month Change
+21.6%
1 Year Change
-2.1%
Year-to-Date Change
-5.3%
From 52W High of $321.12
+24.4%
From 52W Low of $244.54
📊 TOP ANALYST CALLS
Did BIO.B Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bio-Rad is one of their latest high-conviction picks.
Latest BIO.B Stock Price Targets & Analyst Predictions
BIO.B has shown a year-to-date change of -2.1% and a 1-year change of 21.6%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for BIO.B. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BIO.B Analyst Ratings
0
Buy
0
Hold
0
Sell
BIO.B Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $304.15
Latest BIO.B Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BIO.B.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 30, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $375.00 |
| Oct 30, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $340.00 |
| Aug 1, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $409.00 |
| Aug 1, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $265.00 |
| Jun 9, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $245.00 |
| May 2, 2025 | UBS | Dan Leonard | Buy | Maintains | $310.00 |
| May 2, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $350.00 |
| May 2, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $392.00 |
| Apr 17, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $270.00 |
| Feb 12, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $345.00 |
| Jan 14, 2025 | RBC Capital | Conor McNamara | Outperform | Reiterates | $481.00 |
| Dec 9, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $481.00 |
| Oct 31, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $450.00 |
| Oct 31, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $469.00 |
| Oct 1, 2024 | Citigroup | Patrick Donnelly | Buy | Upgrade | $400.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Equal-Weight | Initiates | $340.00 |
| Aug 16, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $401.00 |
| Aug 2, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $401.00 |
| Aug 2, 2024 | Citigroup | Patrick Donnelly | Neutral | Maintains | $350.00 |
| Jun 3, 2024 | Jefferies | Hold | Assumes | $315.00 |
Bio-Rad Laboratories, Inc. (BIO.B) Competitors
The following stocks are similar to Bio-Rad based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bio-Rad Laboratories, Inc. (BIO.B) Financial Data
Bio-Rad Laboratories, Inc. has a market capitalization of $8.14B with a P/E ratio of 50.5x. The company generates $2.59B in trailing twelve-month revenue with a 6.5% profit margin.
Revenue growth is +1.1% quarter-over-quarter, while maintaining an operating margin of +5.8% and return on equity of +2.5%.
Valuation Metrics
Market Cap
$8.14B
Enterprise Value
$7.95B
P/E Ratio
50.5x
PEG Ratio
-0.1x
Price/Sales
3.1x
Growth & Margins
Revenue Growth (YoY)
+1.1%
Gross Margin
+52.3%
Operating Margin
+5.8%
Net Margin
+6.5%
EPS Growth
+1.1%
Financial Health
Cash/Price Ratio
+19.2%
Current Ratio
3.2x
Debt/Equity
20.1x
ROE
+2.5%
ROA
+1.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bio-Rad Laboratories, Inc. (BIO.B) Business Model
About Bio-Rad Laboratories, Inc.
What They Do
Develops advanced analytical and diagnostic technologies.
Business Model
Bio-Rad Laboratories generates revenue by providing a wide range of products and systems for laboratories, including PCR instruments, chromatography systems, and immunoassays. These products cater to various applications in life sciences and clinical diagnostics, serving sectors such as healthcare and research institutions.
Additional Information
Founded in 1952, Bio-Rad has established itself as a trusted partner in scientific exploration and healthcare. The company's innovative solutions are critical for genomics, proteomics, and food safety applications, highlighting its pivotal role in enhancing laboratory efficiency and accuracy.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
7,450
CEO
Mr. Norman D. Schwartz
Country
United States
IPO Year
1999
Website
www.bio-rad.comBio-Rad Laboratories, Inc. (BIO.B) Latest News & Analysis
Latest News
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
9 months ago
Quick Summary
The U.S. plans a 40% cut to the NIH budget in 2026, potentially impacting Bio-Rad. The company projects 0.5% revenue growth for 2025 and is deemed to trade at fair value based on mixed valuations.
Why It Matters
A 40% NIH budget cut could reduce funding for research, impacting Bio-Rad's growth. Projected low revenue growth and mixed valuations indicate potential stagnation for investors.
Source: Seeking Alpha
Market Sentiment:
Negative
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
10 months ago
Quick Summary
Bio-Rad Laboratories, Inc. (BIO) reported second-quarter financial results that exceeded expectations.
Why It Matters
Better-than-expected quarterly results can signal strong company performance, potentially boosting investor confidence and stock price for Bio-Rad Laboratories.
Source: Benzinga
Market Sentiment:
Positive
Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit
1 year ago
Quick Summary
Bio-Rad Laboratories reported third-quarter profits exceeding Wall Street expectations, driven by increased demand for analytical tools and steady growth in clinical diagnostics sales.
Why It Matters
Bio-Rad's stronger-than-expected profits indicate robust demand in biotech and steady growth in clinical diagnostics, signaling potential for future revenue increases and investment confidence.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Bio-Rad Laboratories lowered its annual revenue growth forecast due to decreased demand for clinical diagnostics products from biotech clients.
Why It Matters
Bio-Rad's lowered revenue forecast signals declining demand in the biotech sector, potentially impacting stock performance and investor confidence in related markets.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Bio Rad Laboratories maintained its 2024 sales growth forecast, citing ongoing weak spending from biotech firms and reduced demand in China.
Why It Matters
Bio Rad's reaffirmed 2024 sales growth forecast signals ongoing challenges in biotech spending and demand in China, potentially affecting revenue and stock performance.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Bio-Rad Laboratories reduced its annual revenue growth forecast due to uncertainties in the biopharma sector, causing shares to drop approximately 11% in after-hours trading.
Why It Matters
Lowered revenue forecasts signal potential operational struggles, affecting future profitability and investor confidence, leading to a significant drop in share price.
Source: Reuters
Market Sentiment:
Negative
Frequently Asked Questions About BIO.B Stock
What is Bio-Rad Laboratories, Inc.'s (BIO.B) stock forecast for 2026?
Analyst forecasts for Bio-Rad Laboratories, Inc. (BIO.B) are not currently available. The stock is trading at $304.15.
Is BIO.B stock a good investment in 2026?
Analyst ratings for BIO.B are not currently available. The stock is currently trading at $304.15. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BIO.B stock?
Price predictions from Wall Street analysts for BIO.B are not currently available. The stock is trading at $304.15.
What is Bio-Rad Laboratories, Inc.'s business model?
Bio-Rad Laboratories generates revenue by providing a wide range of products and systems for laboratories, including PCR instruments, chromatography systems, and immunoassays. These products cater to various applications in life sciences and clinical diagnostics, serving sectors such as healthcare and research institutions.
What is the highest forecasted price for BIO.B Bio-Rad Laboratories, Inc.?
Price targets from Wall Street analysts for BIO.B are not currently available. The stock is trading at $304.15.
What is the lowest forecasted price for BIO.B Bio-Rad Laboratories, Inc.?
Price targets from Wall Street analysts for BIO.B are not currently available. The stock is trading at $304.15.
What is the overall BIO.B consensus from analysts for Bio-Rad Laboratories, Inc.?
Analyst ratings for BIO.B are not currently available. The stock is trading at $304.15.
How accurate are BIO.B stock price projections?
Stock price projections, including those for Bio-Rad Laboratories, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 2:13 AM UTC